In this issue:
- FDG PET-CT in assessing stage 1A NSCLC
- EBUS-TBNA in LC staging and diagnosis
- Microwave ablation for NSCLC with IPF
- Asbestos-related LC
- Early LC blood biomarkers
- Resectable NSCL:
– Perioperative nivolumab
– Perioperative tislelizumab
- Lurbinectedin in SCLC: Real-world experience
- EGFR-mutated NSCLC:
– Progression after osimertinib
– Capmatinib plus nazartinib
Please login below to download this issue (PDF)